Both men and women with rheumatoid arthritis (RA) have a higher risk of heart attack than the general population, possibly due to the inflammation associated with RA. In fact Acute Coronary Syndrome (ACS) is one of the major causes of morbidity and mortality in RA. In addition, when compared with people without RA, people with RA may experience worse long-term outcomes after a heart attack.1
Rheumatoid arthritis is an autoimmune condition that affects an estimated 1.3 million people in the United States. In addition to causing pain, swelling, and stiffness of joints, the condition can affect multiple organs and body systems. What remains less clear is what measures individuals with RA need to be taken to modify the risk of this cardiac related morbidity and mortality.
The results of a recently published nationwide population-based clinical study sought to evaluate the effectiveness of treatment options and treatment algorithms in reduction of ACS in RA patients.
Newly diagnosed RA patients (Diagnosis within 12 month of symptom onset) from the Swedish Rheumatology Quality (SRQ) were matched and compared with individuals from the Swedish Population Register. Patients with preexisting ACS were excluded.
Overall 15,744 patients with RA and 70,899 comparator subjects were analyzed. In both groups the incidence of ACS was higher among men and with increased with age. Rheumatoid arthritis was found to be associated with approximately 40% higher risk of ACS. The ACS risk was higher in seropositive RA and in patients with DAS28 above 3.2 at diagnosis.
The occurrence of ACS was higher in the first year after diagnosis of RA, and the authors speculated that use of prescribed or over-the-counter COX inhibitors or oral glucocorticoids during the first months of RA disease and high disease activity may further contribute to the increased morbidity during the first year.
The study suggests that patients with RA may have benefit from the cardiovascular disease prevention and risk factors identification and intervention. Importantly a 2013 study has demonstrated that TNF inhibitors, intended to control inflammation, may reduce the risk of heart attack. TNF inhibitors include Enbrel® (etanercept), Remicade® (infliximab), Humira® (adalimumab), Cimzia® (certolizumab), and Simponi® (golimumab).3
Tags: acute coronary syndrome, adalimumab, certolizumab, Cimzia, enbrel, etanercept, golimumab, Heart Attack, heart disease, humira, infliximab, News Tips and Features, remicade, rheumatoid arthritis, Simponi, TNF inhibitors, Uncategorized